Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
Status:
Completed
Trial end date:
2008-09-08
Target enrollment:
Participant gender:
Summary
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual
to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis.
Non-diabetics with IR are at risk, but can be difficult to diagnose.
A major problem with the use of IR as a predictor or marker of disease is the lack of a
simple, robust test that can be used to quantify this parameter in a wide variety of clinical
situations. The current 'gold standard' methods for measuring insulin sensitivity, such as
the hyperinsulinemic-euglycemic (H-E) clamp, are complex, time consuming and costly.
Alternative, simpler methods, such as the Homeostasis Model Assessment (HOMA-IR) score, may
be less accurate and are not widely accepted.